Adjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M): preplanned interim results from a multicentre, open-label, randomised controlled phase 3 study. (Q52839795)
Jump to navigation
Jump to search
scientific article published on 15 April 2014
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Adjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M): preplanned interim results from a multicentre, open-label, randomised controlled phase 3 study. |
scientific article published on 15 April 2014 |
Statements
Adjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M): preplanned interim results from a multicentre, open-label, randomised controlled phase 3 study. (English)
Pippa G Corrie
Andrea Marshall
Janet A Dunn
Mark R Middleton
Paul D Nathan
Martin Gore
Neville Davidson
Steve Nicholson
Charles G Kelly
Maria Marples
Sarah J Danson
Ernest Marshall
Stephen J Houston
Ruth E Board
Ashita M Waterston
Jenny P Nobes
Mark Harries
Satish Kumar
Gemma Young
15 April 2014
15
6
620-630